Revenue grew 8% year-over-year to €3.4m in Q2 2026, driven by Lifecare's double-digit growth and the successful US launch of RTM. Adjusted EBITDA margin was 34%, with strong cash generation and a non-dilutive share buyback set for August 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.